Amgen

Open: 264.79 Close: 264.59 Change: -0.2

Stop waiting time to find out about Amgen Stock: Our AI summarizes all info about it.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, Inc, biotechnology, earnings, share, current, and the most common words in the summary are: amgen, job, stock, market, price, pdf, kb, . One of the sentences in the summary was: Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and the Nasdaq-100 index. Amgen has on average historically risen by 29.5% based on the past 40 years of stock performance.

Today's News

Amgen Inc. is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. Amgen is expected to post earnings of $4.69 per share for the current quarter, representing a year-over-year change of +14.7%. Amgen has been one of the most searched-for stocks on Zacks. Amgen launches Enbrel Mini with autotouch in U.S. Amgen will present data from two late-breaking abstracts at the European Society for Medical Oncology (ESMO) Congress 2023. Results from Amgen-sponsored and collaborative studies will feature data in a range of tough-to-treat cancers. Tarlatamab is an investigational, targeted immunotherapy engineered by Amgen researchers. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and the Nasdaq-100 index. Amgen has on average historically risen by 29.5% based on the past 40 years of stock performance. Amgen stock has risen higher in 26 of those 40 years over the subsequent 52-week period, corresponding to a historical accuracy of 65% Amgen Stock Price History: Amgen. Amgen is one of the largest independent biotechnology firms in the world. Founded in 1980, Amgen has been involved in groundbreaking research and development efforts, contributing significantly to advancements in biotechnology and healthcare. Amgen has established strong relationships with healthcare providers, distributors, and other stakeholders in the healthcare ecosystem. Bargaining power of suppliers for Amgen is moderate to high depending on specific factors within the biopharmaceutical industry. The level of industry rivalry in the pharmaceutical sector is high. Amgen Inc. is Overvalued by 16% compared to the current market price of 264.59 USD. The intrinsic value of one AMGN stock under the Base Case scenario is 221.75 USD. Amgen is seeking a highly motivated NGS Bioinformatics Intern to join the Ecosystem team in our Therapeutic Discovery organization. The employee data is based on information from people who have self-reported their past or current employments at Amgen. Amgen Inc. – Consensus ‘buy rating and -5.7% downside potential. amgen inc. - Consensus Indicates Potential 11.6% Upside Potential. Amgen is cutting 450 members of its workforce, according to a Reuters report. Amgen (AMGN) reported earnings of $4.96 per share, beating the Zacks Consensus Estimate of $ 4.65 per share. In 2022, Amgens revenue was $26.32 billion, an increase of 1.32% compared to the previous years $25.98 billion. Amgen Inc.s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. Amgen earlier this month acquired Horizon Therapeutics for $27.8 billion. Japan and Asia Pacific (JAPAC) is the fastest growing region in Amgen. Senior Strategic Sourcing Associate in Kuala Lumpur, Malaysia.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, Inc, biotechnology, earnings, share, current, and the most common words in the summary are: amgen, job, stock, market, price, pdf, kb, . One of the sentences in the summary was: Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and the Nasdaq-100 index. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #job #stock #market #price #pdf #kb.